Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Aims to achieve CDMO sales of US$ 400 million by 2028
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Subscribe To Our Newsletter & Stay Updated
